| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies
|
Sonnichsen, Daryl
|
|
2013
|
71 |
6 |
p. 1599-1607
|
artikel
|
| 2 |
Anti-tumor action of trichosanthin, a type 1 ribosome-inactivating protein, employed in traditional Chinese medicine: a mini review
|
Sha, Ou
|
|
2013
|
71 |
6 |
p. 1387-1393
|
artikel
|
| 3 |
A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer
|
Hata, Taishi
|
|
2013
|
71 |
6 |
p. 1657-1663
|
artikel
|
| 4 |
A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer
|
Amato, Robert
|
|
2013
|
71 |
6 |
p. 1629-1634
|
artikel
|
| 5 |
A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin®) in cancer patients
|
Kanai, Masashi
|
|
2013
|
71 |
6 |
p. 1521-1530
|
artikel
|
| 6 |
A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer
|
Kim, Kyu-pyo
|
|
2013
|
71 |
6 |
p. 1609-1617
|
artikel
|
| 7 |
Bevacizumab and central nervous system (CNS) hemorrhage
|
Letarte, Nathalie
|
|
2013
|
71 |
6 |
p. 1561-1565
|
artikel
|
| 8 |
Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer
|
Cortejoso, Lucía
|
|
2013
|
71 |
6 |
p. 1463-1472
|
artikel
|
| 9 |
Differing effects of adjuvant chemotherapy according to BRCA1 nuclear expression in gastric cancer
|
Kim, Jin Won
|
|
2013
|
71 |
6 |
p. 1435-1443
|
artikel
|
| 10 |
Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors
|
Tan, Antoinette R.
|
|
2013
|
71 |
6 |
p. 1635-1643
|
artikel
|
| 11 |
Efficacy and safety of ixabepilone in taxane-resistant patients with metastatic breast cancer previously treated with anthracyclines: results of a phase II study in Japan
|
Aogi, Kenjiro
|
|
2013
|
71 |
6 |
p. 1427-1433
|
artikel
|
| 12 |
Efficacy of bevacizumab-containing chemotherapy for non-squamous non-small cell lung cancer with bone metastases
|
Tokito, Takaaki
|
|
2013
|
71 |
6 |
p. 1493-1498
|
artikel
|
| 13 |
Evaluation of the relationship between cetuximab therapy and corrected QT interval changes in patients with advanced malignancies from solid tumors
|
Deeken, J. F.
|
|
2013
|
71 |
6 |
p. 1473-1483
|
artikel
|
| 14 |
Pharmacokinetics and metabolism of SL-01, a prodrug of gemcitabine, in rats
|
Zhao, Cuirong
|
|
2013
|
71 |
6 |
p. 1541-1550
|
artikel
|
| 15 |
Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer
|
Patnaik, Amita
|
|
2013
|
71 |
6 |
p. 1499-1506
|
artikel
|
| 16 |
Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901
|
Kim, Young Hak
|
|
2013
|
71 |
6 |
p. 1445-1451
|
artikel
|
| 17 |
Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer
|
Kim, Hyeong Su
|
|
2013
|
71 |
6 |
p. 1591-1597
|
artikel
|
| 18 |
Phase II trial of neoadjuvant docetaxel and cisplatin followed by intensity-modulated radiotherapy with concurrent cisplatin in locally advanced nasopharyngeal carcinoma
|
Zhong, Ya Hua
|
|
2013
|
71 |
6 |
p. 1577-1583
|
artikel
|
| 19 |
Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors
|
Yamamoto, Noboru
|
|
2013
|
71 |
6 |
p. 1645-1655
|
artikel
|
| 20 |
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
|
Britten, Carolyn D.
|
|
2013
|
71 |
6 |
p. 1395-1409
|
artikel
|
| 21 |
Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia
|
Hayes, Siobhan
|
|
2013
|
71 |
6 |
p. 1507-1520
|
artikel
|
| 22 |
Potential drug–drug interactions at a referral hematology–oncology ward in Iran: a cross-sectional study
|
Hadjibabaie, Molouk
|
|
2013
|
71 |
6 |
p. 1619-1627
|
artikel
|
| 23 |
Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma
|
Chan, Stephen L.
|
|
2013
|
71 |
6 |
p. 1417-1425
|
artikel
|
| 24 |
Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo
|
Escalante, Aluvia M.
|
|
2013
|
71 |
6 |
p. 1567-1576
|
artikel
|
| 25 |
Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy
|
Vichaya, Elisabeth G.
|
|
2013
|
71 |
6 |
p. 1531-1540
|
artikel
|
| 26 |
Switching to a low-fat diet attenuates the intensified doxorubicin cardiotoxicity associated with high-fat feeding
|
Hydock, David S.
|
|
2013
|
71 |
6 |
p. 1551-1560
|
artikel
|
| 27 |
Taxane-sensitivity of ovarian carcinomas previously treated with paclitaxel and carboplatin
|
Ueda, Yutaka
|
|
2013
|
71 |
6 |
p. 1411-1416
|
artikel
|
| 28 |
The elimination of MTC-220, a novel anti-tumor agent of conjugate of paclitaxel and muramyl dipeptide analogue, in rats
|
You, Feng
|
|
2013
|
71 |
6 |
p. 1453-1462
|
artikel
|
| 29 |
Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer
|
Sohal, Davendra P. S.
|
|
2013
|
71 |
6 |
p. 1485-1491
|
artikel
|
| 30 |
Treatment of malignant ascites with a combination of chemotherapy drugs and intraperitoneal perfusion of verapamil
|
Jia, Weidong
|
|
2013
|
71 |
6 |
p. 1585-1590
|
artikel
|
Tijdschrift beschrijving